Study on preparation of Fe₃O₄@lapatinib nanoparticles for application as a targeted drug delivery system in the treatment of breast cancer
Main Article Content
Abstract
: Systems for targeted drug delivery in the treatment of cancer using nanoparticles are currently of interest to many domestic and foreign scientists. In this work, for application as a target drug delivery system in the treatment of breast cancer Fe3O4@lapatinib nanoparticles were prepared by coprecipitation of solutions of Fe2+ and Fe3+ salts in alkaline, followed by purification in a magnetic separation system. Physicochemical properties of nanoparticles were studied and determined by XRD, TEM, DLS, HPLC, VSM, AAS and zeta potential methods. The results showed that the size of Fe3O4@lapatinib nanoparticles is in the range of 10 to 40 nm, hydrodynamic diameter is 27.4 ± 0.6 nm, saturation magnetization is 39.1 ± 3.1 emu/g, Fe content is 16.35 ± 0.97 mg/ml, lapatinib content is 8.08 ± 0.06 mg/ml, and the zeta potential is -16.2 ± 1.3 mV. Thus, the obtained Fe3O4@lapatinib nanoparticles are fully suitable for targeted drug delivery in the breast cance treatment
Article Details
Keywords
Fe3O4@lapatinib nanoparticles, co-precipitation, breast cancer, targeted drug delivery
References
[2]. Ministry of Health, List of 9498 techniques in medical test and treatment performed at Bach Mai Hospital, (2014).
[3]. Beverly Moy, et al., "Lapatinib", Nature reviews drug discovery, 6, pp (2007), 10.1038/nrd2332.
[4]. Nguyen Thi Kim Thanh, "Clinical Applications of Magnetic Nanoparticles", CRC Press, pp <4-54>, 2018, https://doi.org/10.1201/9781315168258
[5]. Domenico Bilancia, et al., "Lapatinib in breast cancer", Annals of Oncology, 18 Suppl 6, pp
[6]. Rüdiger Lawaczeck, Michael Menzel, Pietsch, Hubertus, "Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging", Applied Organometallic Chemistry, 18, pp <506-513>, (2004), https://doi.org/10.1002/aoc.753.
[7]. Qiyi Feng, et al., "Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings", Scientific Reports, 8, pp <2082>, (2018), 10.1038/s41598-018-19628-z.
[8]. Luong Huynh Vu Thanh, et al., "Synthesis of surface functionalized Fe3O4@SiO2 nanomaterials with chitosan", Can Tho University Science Magazine, 57, pp <10-20>, (2021), 10.22144 /ctu.jvn.2021.032.
[9]. Dhrisya Chenthamara, et al., "Therapeutic efficacy of nanoparticles and routes of administration", Biomaterials Research, 23, pp <20>, (2019), 10.1186/s40824-019-0166-x.
[10]. Li Tang, et al., "Investigating the optimal size of anticancer nanomedicine", Proc Natl Acad Sci U S A, 111, pp <15344-9>, (2014), 10.1073/pnas.1411499111.
[11]. Nazanin Hoshyar, et al., "The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction", Nanomedicine (Lond), 11, pp <673-92>, (2016), 10.2217/nnm.16.5.
[12].Yudelson, Joseph S., "Preparation and magnetic properties of very small magnetite-dextran particles", United States Patent, (1994).
[13]. Dhirender Singh, et al., "Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues", Nanomedicine (Lond), 9, pp <469-85>, (2014), 10.2217/nnm.14.4.
[14]. Patricia A Hudgins, et al., "Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study", American Journal of Neuroradiology, 23, pp <649-56>, (2002).
[15].McHenry, M.E., "Magnetic Steels",
Encyclopedia of Materials: Science and Technology, pp.< 4961-4964>, (2001).
[16]. Jeffrey D Clogston, Patri, Anil K, "Zeta potential measurement", Methods Mol Biol, 697, pp <63-70>, (2011), 10.1007/978-1-60327-198-1_6.
[17]. Magdalena Kędzierska, et al., "The Synthesis Methodology of PEGylated Fe(3)O(4)@Ag Nanoparticles Supported by Their Physicochemical Evaluation", Molecules, 26, pp <1-17>, (2021), 10.3390/molecules26061744.